Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].

Psychiatria polska - 1 Jan 2000

Jarema M

Abstract excerpt

About 5-10% of European white population has a genetically determinant defect of the CYP2D6, one of the enzymes of cytochrome P-450. This defect leads to the impaired metabolism of many drugs including various psychopharmacological agents. The measurement of the hydroxylation of debrisoquine is a laboratory test which allows to identify such an individual. Patients who show an impaired hydroxylation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cytochrome P-450 Enzyme System
Share to Debrisoquin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hydroxylation

Share to Phenotype

Source

Identifiers

PMID: 7878155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].PMID 7878155Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].Semantic proximity Read ↗

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].Semantic proximity Read ↗

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

[Genetic polymorphism in human drug metabolism].Semantic proximity Read ↗

Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.Semantic proximity Read ↗

Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.Semantic proximity Read ↗

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.Semantic proximity Read ↗

[Assessment of biotransformation capacity following oral administration of various model substances as cocktail].Semantic proximity Read ↗

Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping.Semantic proximity Read ↗

Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.